Clinuvel Pharmaceuticals (ASX:CUV) said it is in talks with the European Medicines Agency (EMA) to increase the recommended maximum dose of its drug Scenesse for adult patients with erythropoietic protoporphyria (EPP), according to a Wednesday filing with the Australian bourse.
EPP is an inherited condition characterized by extreme photosensitivity and could lead to liver disease.
The EMA's Pharmacovigilance Risk Assessment Committee will decide whether to maintain the existing drug label or expand it to up to six times per year, the filing said.
The outcome is expected by the first quarter of 2025, according to the filing.
Clinuvel Pharmaceuticals' shares were down more than 2% in recent Wednesday trade.
Price (AUD): $13.30, Change: $-0.32, Percent Change: -2.39%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。